Related Experiment Video
Updated: Mar 20, 2026
07:31
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
4.4K
The pharmacogenomics of osteosarcoma
1Laboratory of Experimental Oncology, Orthopaedic Rizzoli Institute, Bologna, Italy.
The Pharmacogenomics Journal
|June 1, 2016
Summary
Identifying pharmacogenomic biomarkers for osteosarcoma (OS) is crucial. These biomarkers can personalize chemotherapy, improving outcomes and reducing toxicities for bone cancer patients.
Area of Science:
- Oncology
- Pharmacogenomics
- Bone Cancer Research
Background:
- Osteosarcoma (OS) is the most common bone malignancy.
- Current chemotherapy cures 60-65% of patients but causes unpredictable toxicities.
- Need for personalized treatments to enhance efficacy and minimize adverse events.
Purpose of the Study:
- To review identified pharmacogenomic biomarkers in OS.
- To highlight biomarkers with potential for clinical translation.
- To support personalized medicine in osteosarcoma treatment.
Main Methods:
- Literature review of pharmacogenomic studies in osteosarcoma.
- Analysis of identified biomarkers for OS treatment.
- Assessment of biomarker potential for patient stratification and toxicity prediction.
Main Results:
- Several pharmacogenomic biomarkers have been identified in OS.
- These biomarkers show promise for predicting treatment response.
- Potential to identify patients at higher risk of treatment-associated toxicity.
Conclusions:
- Pharmacogenomic biomarkers are essential for personalized osteosarcoma therapy.
- Further validation is needed for clinical application.
- Biomarkers can improve therapeutic benefits and reduce OS treatment toxicity.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
65
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
102
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
102
01:29Pharmacogenetics and Pharmacogenomics: Overview
135
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
135
01:29Pharmacogenomics: Identification of New Drug Targets
75
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75
01:27Pharmacogenetics of Drug Metabolism: Overview
101
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
101
01:27Principles of Pharmacogenetics: Types of Genetic Variants
86
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
86